Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PMV Pharmaceuticals, Inc.
Report date September 29, 2020 · Filed September 29, 2020
Jointly reported with Nextech V Oncology S.C.S., SICAV-SIF, NEXTECH V GP S.A R.L., Lips Thomas, Detournay Philippe
Section 16 reporting ended · disclosed 2020-09-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,528,290 |
Last balance in matching sequence
After 2020-09-29 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-09-29 · Conversion · Acquired 1,768,023 · Balance 1,768,023 F1: The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. Thilo Schroeder is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. Mr. Schroeder is a director of the Issuer and files separate Section 16 reports. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV SIF. Dalia Bleyer, Philippe Detournay and Thomas Lips are Managers of Nextech V GP S.a r.l. and each of Nextech V GP S.a r.l., Ms. Bleyer and Messrs. Detournay and Lips may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership over such shares, except to the extent of his, her or its respective pecuniary interest therein, if any. Row 2 · 2020-09-29 · Conversion · Acquired 760,267 · Balance 2,528,290 F1: The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. Thilo Schroeder is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. Mr. Schroeder is a director of the Issuer and files separate Section 16 reports. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV SIF. Dalia Bleyer, Philippe Detournay and Thomas Lips are Managers of Nextech V GP S.a r.l. and each of Nextech V GP S.a r.l., Ms. Bleyer and Messrs. Detournay and Lips may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership over such shares, except to the extent of his, her or its respective pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-09-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-09-29 · Conversion · Disposed 1,768,023 · Balance 0 F1: The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. Thilo Schroeder is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. Mr. Schroeder is a director of the Issuer and files separate Section 16 reports. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV SIF. Dalia Bleyer, Philippe Detournay and Thomas Lips are Managers of Nextech V GP S.a r.l. and each of Nextech V GP S.a r.l., Ms. Bleyer and Messrs. Detournay and Lips may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership over such shares, except to the extent of his, her or its respective pecuniary interest therein, if any. |
| Series D Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-09-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-09-29 · Conversion · Disposed 760,267 · Balance 0 F1: The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. Thilo Schroeder is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. Mr. Schroeder is a director of the Issuer and files separate Section 16 reports. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV SIF. Dalia Bleyer, Philippe Detournay and Thomas Lips are Managers of Nextech V GP S.a r.l. and each of Nextech V GP S.a r.l., Ms. Bleyer and Messrs. Detournay and Lips may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership over such shares, except to the extent of his, her or its respective pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
F2: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. Thilo Schroeder is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. Mr. Schroeder is a director of the Issuer and files separate Section 16 reports. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV SIF. Dalia Bleyer, Philippe Detournay and Thomas Lips are Managers of Nextech V GP S.a r.l. and each of Nextech V GP S.a r.l., Ms. Bleyer and Messrs. Detournay and Lips may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership over such shares, except to the extent of his, her or its respective pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 29, 2020 Filed Sep 29, 2020 20:49 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionSeries D Preferred Stock · Derivative | 760,267 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052353 · doc4.xml · derivative · entry 4 Nextech V Oncology S.C.S., SICAV-SIF · CIK 0001712922 · Former 10% Owner NEXTECH V GP S.A R.L. · CIK 0001826326 · Former 10% Owner Bleyer Dalia · CIK 0001826431 · Former 10% Owner Lips Thomas · CIK 0001826413 · Former 10% Owner Detournay Philippe · CIK 0001826386 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 760,267 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.direct: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. Thilo Schroeder is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. Mr. Schroeder is a director of the Issuer and files separate Section 16 reports. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV SIF. Dalia Bleyer, Philippe Detournay and Thomas Lips are Managers of Nextech V GP S.a r.l. and each of Nextech V GP S.a r.l., Ms. Bleyer and Messrs. Detournay and Lips may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership over such shares, except to the extent of his, her or its respective pecuniary interest therein, if any. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 20:49 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionSeries C Preferred Stock · Derivative | 1,768,023 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052353 · doc4.xml · derivative · entry 3 Nextech V Oncology S.C.S., SICAV-SIF · CIK 0001712922 · Former 10% Owner NEXTECH V GP S.A R.L. · CIK 0001826326 · Former 10% Owner Bleyer Dalia · CIK 0001826431 · Former 10% Owner Lips Thomas · CIK 0001826413 · Former 10% Owner Detournay Philippe · CIK 0001826386 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,768,023 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.direct: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. Thilo Schroeder is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. Mr. Schroeder is a director of the Issuer and files separate Section 16 reports. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV SIF. Dalia Bleyer, Philippe Detournay and Thomas Lips are Managers of Nextech V GP S.a r.l. and each of Nextech V GP S.a r.l., Ms. Bleyer and Messrs. Detournay and Lips may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership over such shares, except to the extent of his, her or its respective pecuniary interest therein, if any. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 20:49 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionCommon Stock | 760,267 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052353 · doc4.xml · nonDerivative · entry 2 Nextech V Oncology S.C.S., SICAV-SIF · CIK 0001712922 · Former 10% Owner NEXTECH V GP S.A R.L. · CIK 0001826326 · Former 10% Owner Bleyer Dalia · CIK 0001826431 · Former 10% Owner Lips Thomas · CIK 0001826413 · Former 10% Owner Detournay Philippe · CIK 0001826386 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,528,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.direct: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. Thilo Schroeder is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. Mr. Schroeder is a director of the Issuer and files separate Section 16 reports. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV SIF. Dalia Bleyer, Philippe Detournay and Thomas Lips are Managers of Nextech V GP S.a r.l. and each of Nextech V GP S.a r.l., Ms. Bleyer and Messrs. Detournay and Lips may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership over such shares, except to the extent of his, her or its respective pecuniary interest therein, if any. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 20:49 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionCommon Stock | 1,768,023 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052353 · doc4.xml · nonDerivative · entry 1 Nextech V Oncology S.C.S., SICAV-SIF · CIK 0001712922 · Former 10% Owner NEXTECH V GP S.A R.L. · CIK 0001826326 · Former 10% Owner Bleyer Dalia · CIK 0001826431 · Former 10% Owner Lips Thomas · CIK 0001826413 · Former 10% Owner Detournay Philippe · CIK 0001826386 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,768,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.direct: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. Thilo Schroeder is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. Mr. Schroeder is a director of the Issuer and files separate Section 16 reports. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV SIF. Dalia Bleyer, Philippe Detournay and Thomas Lips are Managers of Nextech V GP S.a r.l. and each of Nextech V GP S.a r.l., Ms. Bleyer and Messrs. Detournay and Lips may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership over such shares, except to the extent of his, her or its respective pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.